Portfolio company SpyGlass Pharma priced its initial public offering (NASDAQ: SGP).
SpyGlass Pharma is pioneering sustained drug delivery for the management of chronic eye diseases, specifically uniting glaucoma and cataract treatment to enhance patient care
SpyGlass Pharma is pioneering sustained drug delivery for the management of chronic eye diseases, specifically uniting glaucoma and cataract treatment to enhance patient care.